^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Endometrial Cancer
    Drug:Rubraca (rucaparib) (PARP inhibitor) +
    Trodelvy (sacituzumab govitecan-hziy) (Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2020
    Title:

    547P - Rucaparib + sacituzumab govitecan (SG): Initial data from the phase Ib/II SEASTAR study (NCT03992131)

    Published date:
    09/14/2020
    Excerpt:
    Three pts had a confirmed PR, including 2 pts previously treated with niraparib until PD; 2 responders did not have HRR gene mutations….Table: 547P...Initial encouraging signs of antitumour activity were seen with rucaparib + SG in pts with advanced solid tumours, including pts with prior PARPi exposure.
    Trial ID:
    SEASTAR